Role of fat-derived substrates in the regulation of gluconeogenesis during fasting.
To determine the role of fat-derived substrates in the regulation of glucose metabolism during fasting, glucose turnover, urea nitrogen production, alanine conversion to glucose, and substrate oxidation rates were measured in 34 normal 4-day-fasted volunteers treated with the antilipolytic drug acipimox or placebo for 8 h. The approximately 50% inhibition of lipolysis induced by acipimox increased glucose concentration and production, respectively, by approximately 35 and approximately 30%, whereas the protein breakdown and the amount of alanine converted to glucose were increased, respectively, by approximately 70 and approximately 85%. Insulin levels were reduced by approximately 40%, cortisol levels doubled, and growth hormone concentration increased sevenfold. The relative contribution of free fatty acid (FFA) and ketone body lowering to the observed response was evaluated in nine acipimox-treated subjects in whom ketone body concentration was clamped with an intravenous beta-hydroxybutyrate infusion. The results of these experiments suggest that, during fasting, both FFA and ketone bodies tend to suppress gluconceogenesis and to protect the protein stores. FFA seem to exert their effects mainly through their ability to modulate the hormonal milieu (especially insulin), whereas ketone bodies seem to act mainly by other mechanisms. Thus the widespread view according to which FFA exert a stimulatory role on gluconeogenesis does not apply to the fasting state in vivo.
Féry
F
F
Department of Endocrinology, Hopital Erasme, University of Brussels, Belgium.
Plat
L
L
Melot
C
C
Balasse
E O
EO
D020155:3-Hydroxybutyric Acid; D000273:Adipose Tissue / Q000378:metabolism*; D000328:Adult; D005215:Fasting / Q000502:physiology*; D005230:Fatty Acids, Nonesterified / Q000037:antagonists & inhibitors / Q000097:blood / Q000502:physiology; D005260:Female; D005943:Gluconeogenesis / Q000502:physiology*; D006801:Humans; D006885:Hydroxybutyrates / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007657:Ketone Bodies / Q000037:antagonists & inhibitors / Q000097:blood / Q000494:pharmacology; D008297:Male; D011719:Pyrazines / Q000494:pharmacology
D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D000960:Hypolipidemic Agents; D007657:Ketone Bodies; D011719:Pyrazines; C027696:acipimox; D020155:3-Hydroxybutyric Acid